136 related articles for article (PubMed ID: 37023314)
1. Role of the KRT7 Biomarker in Immune Infiltration and Paclitaxel Resistance in Ovarian.
Wang S; Li H; Li M; Liu X; Yu S; Huang H; Wang X
Altern Ther Health Med; 2023 Jul; 29(5):132-140. PubMed ID: 37023314
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer.
Yang J
Med Oncol; 2020 Mar; 37(5):34. PubMed ID: 32219571
[TBL] [Abstract][Full Text] [Related]
3. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
4. A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.
Communal L; Roy N; Cahuzac M; Rahimi K; Köbel M; Provencher DM; Mes-Masson AM
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070214
[TBL] [Abstract][Full Text] [Related]
5. FoxM1 promotes the migration of ovarian cancer cell through KRT5 and KRT7.
Zhang Z; Tu K; Liu F; Liang M; Yu K; Wang Y; Luo Y; Yang B; Qin Y; He D; Jiang G; Huang O; Zou Y
Gene; 2020 Oct; 757():144947. PubMed ID: 32659254
[TBL] [Abstract][Full Text] [Related]
6. KRT7 promotes epithelial‑mesenchymal transition in ovarian cancer via the TGF‑β/Smad2/3 signaling pathway.
An Q; Liu T; Wang MY; Yang YJ; Zhang ZD; Liu ZJ; Yang B
Oncol Rep; 2021 Feb; 45(2):481-492. PubMed ID: 33416175
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor-infiltrating immune cells in ovarian cancer.
Zhang J; Zhang J; Wang F; Xu X; Li X; Guan W; Men T; Xu G
J Cell Physiol; 2021 Oct; 236(10):6907-6919. PubMed ID: 33655494
[TBL] [Abstract][Full Text] [Related]
8. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
9. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
11. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer.
Song J; Ruze R; Chen Y; Xu R; Yin X; Wang C; Xu Q; Zhao Y
BMC Cancer; 2022 Aug; 22(1):894. PubMed ID: 35974300
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Diao B; Yang P
Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
[TBL] [Abstract][Full Text] [Related]
13. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
14. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
16. LncRNA GIHCG promotes development of ovarian cancer by regulating microRNA-429.
Yao N; Yu L; Zhu B; Gan HY; Guo BQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8127-8134. PubMed ID: 30556850
[TBL] [Abstract][Full Text] [Related]
17. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract][Full Text] [Related]
18. Identification of latent biomarkers in connection with progression and prognosis in oral cancer by comprehensive bioinformatics analysis.
Reyimu A; Chen Y; Song X; Zhou W; Dai J; Jiang F
World J Surg Oncol; 2021 Aug; 19(1):240. PubMed ID: 34384424
[TBL] [Abstract][Full Text] [Related]
19. A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.
Zhou M; Chen Y; Gu X; Wang C
Pathol Oncol Res; 2022; 28():1610504. PubMed ID: 36061144
[No Abstract] [Full Text] [Related]
20. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients.
Liu J; Wang Y; Yuan S; Wei J; Bai J
Front Immunol; 2021; 12():751594. PubMed ID: 34745124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
